These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24321399)

  • 1. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
    Sung CO; Song IH; Sohn I
    Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
    Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
    Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.
    Lassus H; Leminen A; Vayrynen A; Cheng G; Gustafsson JA; Isola J; Butzow R
    Gynecol Oncol; 2004 Jan; 92(1):31-9. PubMed ID: 14751135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
    Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
    Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
    Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M
    Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
    Engler DA; Gupta S; Growdon WB; Drapkin RI; Nitta M; Sergent PA; Allred SF; Gross J; Deavers MT; Kuo WL; Karlan BY; Rueda BR; Orsulic S; Gershenson DM; Birrer MJ; Gray JW; Mohapatra G
    PLoS One; 2012; 7(2):e30996. PubMed ID: 22355333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.
    Goundiam O; Gestraud P; Popova T; De la Motte Rouge T; Fourchotte V; Gentien D; Hupé P; Becette V; Houdayer C; Roman-Roman S; Stern MH; Sastre-Garau X
    Int J Cancer; 2015 Oct; 137(8):1890-900. PubMed ID: 25892415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
    Davis SJ; Sheppard KE; Anglesio MS; George J; Traficante N; Fereday S; Intermaggio MP; Menon U; Gentry-Maharaj A; Lubinski J; Gronwald J; Pearce CL; Pike MC; Wu A; Kommoss S; Pfisterer J; du Bois A; Hilpert F; Ramus SJ; Bowtell DD; Huntsman DG; Pearson RB; Simpson KJ; Campbell IG; Gorringe KL
    Mol Cancer Ther; 2015 Jun; 14(6):1495-503. PubMed ID: 25852062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
    Pils D; Bachmayr-Heyda A; Auer K; Svoboda M; Auner V; Hager G; Obermayr E; Reiner A; Reinthaller A; Speiser P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Berger A; Cacsire Castillo-Tong D; Zeillinger R
    Eur J Cancer; 2014 Jan; 50(1):99-110. PubMed ID: 24176298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
    Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
    Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
    BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
    He J; Liu Y; Zhang L; Zhang H
    Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficient molecular subtype classification of high-grade serous ovarian cancer.
    Leong HS; Galletta L; Etemadmoghadam D; George J; ; Köbel M; Ramus SJ; Bowtell D
    J Pathol; 2015 Jul; 236(3):272-7. PubMed ID: 25810134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L; Wang H; Li P
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.
    Shih IeM; Nakayama K; Wu G; Nakayama N; Zhang J; Wang TL
    Mod Pathol; 2011 May; 24(5):638-45. PubMed ID: 21240255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.